Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$0.21
$0.21
$0.21
▼
$3.09
$2.55M0.91482,532 shsN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.41
+3.0%		$0.39
$0.23
▼
$2.75
$8.08M0.977.71 million shs12,080 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.57
+1.3%		$0.87
$0.16
▼
$15.75
$11.18M1.92634,656 shs19,756 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$8K0.688.94 million shs330 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%0.00%0.00%0.00%-86.87%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-3.47%-11.58%-0.72%+32.97%-82.06%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+7.39%-27.32%-7.22%-82.66%-94.67%
ObsEva SA stock logo
OBSV
ObsEva
0.00%-89.90%-89.90%-89.90%-79.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$0.21
$0.21
$0.21
▼
$3.09
$2.55M0.91482,532 shsN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.41
+3.0%		$0.39
$0.23
▼
$2.75
$8.08M0.977.71 million shs12,080 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.57
+1.3%		$0.87
$0.16
▼
$15.75
$11.18M1.92634,656 shs19,756 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$8K0.688.94 million shs330 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%0.00%0.00%0.00%-86.87%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-3.47%-11.58%-0.72%+32.97%-82.06%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+7.39%-27.32%-7.22%-82.66%-94.67%
ObsEva SA stock logo
OBSV
ObsEva
0.00%-89.90%-89.90%-89.90%-79.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
1.00
SellN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.33
Hold$3.00422.65% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CASI, MBRX, ENSC, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$3.00
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$26.85M0.10N/AN/A$0.12 per share1.73
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M1.58N/AN/A$0.63 per share0.65
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$4.69 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$3.01N/AN/AN/A-183.93%N/A-131.54%N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$2.76N/AN/AN/A-280.53%-2,550.30%-320.49%11/13/2026 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$33.56M-$7.13N/AN/AN/AN/A-143.51%-24.53%11/12/2026 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest CASI, MBRX, ENSC, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.20-$0.20N/A-$0.20$1.20 million$1.16 million
8/13/2026Q2 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$1.55-$1.40+$0.15-$1.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.30
0.24
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.70
0.70
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
0.94
0.94
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
18.04%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1019.46 million18.91 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1719.48 million15.96 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
August 31, 2024  |  pharmaphorum.comP
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
April 3, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/03/2856586/0/en/obseva-announces-delisting-from-six-swiss-exchange-and-exemption-from-certain-obligations-associated-with-the-maintenance-of-listin.html
ObsEva SA OBSN
November 11, 2023  |  morningstar.comM
ObsEva SA OBSEF
November 11, 2023  |  morningstar.comM
ObsEva (NASDAQ: OBSV)
June 18, 2023  |  fool.comhttps://www.fool.com/quote/nasdaq/obsv/
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver
May 10, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance
May 2, 2023  |  news.google.comN
ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq
May 2, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire
May 2, 2023  |  news.google.comN
Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Marketscreener.com
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Yahoo Finance
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Benzinga
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - EIN News
April 28, 2023  |  news.google.comN
Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire
April 28, 2023  |  news.google.comN
Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal
April 26, 2023  |  news.google.comN
Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR
April 23, 2023  |  news.google.comN
ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com
April 21, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - Yahoo Finance
April 20, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - GlobeNewswire
April 20, 2023  |  news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)
As of 09/23/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.41 +0.01 (+2.97%)
As of 09:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.57 +0.01 (+1.25%)
As of 09:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas